Document Detail


Medicines discovery in the 21st century: the case for a stakeholder corporation.
MedLine Citation:
PMID:  20678583     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is widely accepted that biopharmaceutical companies have, in recent times, failed to deliver large numbers of new medicines to patients and have simultaneously failed to deliver large financial returns to their investors. We argue that addition of different business constructs with wider stakeholder ownership and/or control offers a way to improve returns from the great advances in medical science and drug discovery processes. Governments and other payers for medicines, the academic institutions engaged in bioscience knowledge creation, patient advocacy groups, venture philanthropists and charitable foundations can come together with commercial profit-centred businesses to develop corporate constructs that mutually benefit all of the stakeholders. A rebalancing of the social and financial motives in medicines research can arrest recent productivity decreases of the sector.
Authors:
John Dixon; Paul England; Geoff Lawton; Peter Machin; Alan Palmer
Related Documents :
10280173 - Product line management: organization makes the difference.
10024743 - The agenda of the organization. 2: interventions.
24716123 - Therapeutic potential of chinese herbal medicines in alcoholic liver disease.
Publication Detail:
Type:  Journal Article     Date:  2010-08-01
Journal Detail:
Title:  Drug discovery today     Volume:  15     ISSN:  1878-5832     ISO Abbreviation:  Drug Discov. Today     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-13     Completed Date:  2011-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  England    
Other Details:
Languages:  eng     Pagination:  700-3     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Church Farmhouse, 24 Main Street, Great Dalby, Melton Mowbray, Leics LE14 2ET, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Discovery / trends*
Drug Industry / organization & administration*
Humans
Public-Private Sector Partnerships

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Signalling through FOXP3 as an X-linked tumor suppressor.
Next Document:  Comparative morphology of the hemolymph vascular system in krill (Euphausiacea; Crustacea).